Floatz logo

Cediranib

Metastatic Kidney Carcinoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Metastatic Kidney Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BBB
Bms-907351
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Ipilimumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Pembrolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 4BB
Cyclophosphamide
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3B

View all 21 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →